Form 4: Director Jean-Jacques Bienaime Buys Keros Therapeutics
Insider Transaction Report
Director Jean-Jacques Bienaime acquired 1,000 shares of Keros Therapeutics, Inc. (KROS) at an average price of $11.70.
Summary
- Director Jean-Jacques Bienaime purchased 1,000 shares of Keros Therapeutics common stock.
- The transaction occurred on April 15, 2026.
- The purchase was executed at a weighted average price of $11.70 per share, with individual prices ranging from $11.56 to $11.80.
- The acquisition was made pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025.
- Following this transaction, the director holds a total of 8,450 shares directly.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a mildly positive signal, as it reflects insider confidence through a structured, non-discretionary purchase plan.
Positives
- Insider confidence is demonstrated by a director purchasing shares with personal capital.
- The transaction was executed under a pre-established Rule 10b5-1 trading plan, indicating a systematic approach to investment rather than reactive trading.
Negatives
- The volume of shares purchased (1,000) is relatively small in the context of total outstanding shares.
Risks
- Market volatility may impact the value of the director's holdings.
- Reliance on Rule 10b5-1 plans does not guarantee future stock performance.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal of management's belief in the long-term clinical or commercial prospects of the company's pipeline.
Comparison to Industry Standards
- Insider purchases via 10b5-1 plans are standard practice for corporate directors to avoid potential conflicts of interest while maintaining equity exposure.
Stakeholder Impact
- Shareholders may interpret the director's purchase as a sign of confidence in the company's current valuation.
Next Steps
- No future milestones or actions were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2025-12-05 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-04-15 | Date of the reported stock purchase transaction. |
| 2026-04-17 | Date the Form 4 was filed with the SEC. |
Keywords
Keros Therapeutics, KROS, Insider Trading, Form 4, Jean-Jacques Bienaime, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.